GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.

MANNHEIM, Germany, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's ...

(RTTNews) - GT Biopharma, Inc. (GTBP) has submitted its investigational new drug (IND) application to the U.S. FDA for GTB-5550 TriKE, a novel natural killer (NK) cell engager designed to target B7-H3 ...

Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- ...

GTB-3650 TriKE ® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend ...